Research from ACF Equity Research, ACF Equity Research

ACF Equity Research

Research from ACF Equity Research

Accuracy | Clarity | Foresight

ACF was set up to improve the effectiveness of capital markets for smaller and mid-sized companies. The majority of jobs are created by smaller companies not global companies. If we can help improve companies use of capital markets more projects will be completed, more jobs created, more global GDP grown, which in turn helps create more resources for education, leading to equality and opportunity for those who are still oppressed by ignorance and poverty.

ACF Equity Research is an independent research house specialising in the highest specification independent equity research for corporate clients.

We deliver premium independent corporate sponsored equity research characterised by its accuracy, clarity and foresight based upon a fundamental valuation approach.

Our independent research is designed to educate our professional investor readers about your company, with an emphasis on clear and accurate explanations. Our mission is to improve company’s liquidity through credible equity research services, excellent international distribution and reliable access for investment managers.

We believe in the importance and value of clarity, the careful articulation of technical ideas, concepts and solutions.

Our team of analysts are independently minded individuals who believe in thoroughness, technical competence and clear punchy communications.

Equity Bottom-Up

<ul><li>Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential.</li><li>In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital.</li><li>Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms.</li></ul>

Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential.In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital.Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms.

Abbvie Inc - Regenerative Healthcare - Stem Cells & ALS Thematic 10062024

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Leading pharmaceutical company AbbVie Inc. has outperformed expectations in its first quarter 2024 results.</li><li>The financial results and current business outlook reflect the strength and momentum of AbbVie's diversified pharmaceutical portfolio, which is projected to have long-term growth prospects.</li><li>The company reported adjusted earnings per share of $2.31 and total net revenues of $12.3 billion, exceeding expectations by $400 million.</li></ul>

Leading pharmaceutical company AbbVie Inc. has outperformed expectations in its first quarter 2024 results.The financial results and current business outlook reflect the strength and momentum of AbbVie's diversified pharmaceutical portfolio, which is projected to have long-term growth prospects.The company reported adjusted earnings per share of $2.31 and total net revenues of $12.3 billion, exceeding expectations by $400 million.

AbbVie Inc.: Acquisition of Landos Biopharma to Enhance Autoimmune Disease Treatments & Other Major Developments

<ul><li>AbbVie Inc.</li><li>showcased a robust performance in the fourth quarter (Q4) of 2023, delivering results surpassing initial expectations.</li><li>The company's growth platform, independent of their iconic Humira, reported full-year sales growth exceeding 8%.</li></ul>

AbbVie Inc.showcased a robust performance in the fourth quarter (Q4) of 2023, delivering results surpassing initial expectations.The company's growth platform, independent of their iconic Humira, reported full-year sales growth exceeding 8%.

AbbVie Inc: Produodopa's Green Light In Scotland & 6 Other Major Developments - Key Drivers

<ul><li>AbbVie Inc. managed to exceed Wall Street's revenue and earnings expectations, reinforcing a positive trajectory for long-term growth.</li><li>The recently reported results exemplify this strength, with adjusted earnings per share reaching $2.95, surpassing the guidance midpoint by $0.14.</li><li>The ex-HUMIRA growth platform stands out as a powerhouse, achieving remarkable revenue growth of over 12% in the quarter.</li></ul>

AbbVie Inc. managed to exceed Wall Street's revenue and earnings expectations, reinforcing a positive trajectory for long-term growth.The recently reported results exemplify this strength, with adjusted earnings per share reaching $2.95, surpassing the guidance midpoint by $0.14.The ex-HUMIRA growth platform stands out as a powerhouse, achieving remarkable revenue growth of over 12% in the quarter.

AbbVie Inc.: Is The Strengthening Neuroscience Pipeline The Key To Future Success? - Major Drivers

<ul><li>AbbVie managed to surpass the revenue expectations as well as the earnings expectations of Wall Street.</li><li>Skyrizi and Rinvoq are exhibiting exceptional growth in immunology, with sales for both treatments increasing over the previous year.</li><li>Skyrizi and Rinvoq are now approved across ten significant indications and are projecting combined revenue growth this year.</li></ul>

AbbVie managed to surpass the revenue expectations as well as the earnings expectations of Wall Street.Skyrizi and Rinvoq are exhibiting exceptional growth in immunology, with sales for both treatments increasing over the previous year.Skyrizi and Rinvoq are now approved across ten significant indications and are projecting combined revenue growth this year.

AbbVie Inc.: Interesting Advancements In Several Preclinical & Early-stage Clinical Assets – Key Drivers

United States

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, Hepatitis C, women's health, oncology, and neuroscience. AbbVie also offers treatments for diseases including Multiple Sclerosis, Parkinson's, and Alzheimer's disease.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Abbvie Inc (ABBV US)

Abbvie Inc - Regenerative Healthcare - Stem Cells & ALS Thematic 10062024

Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation...

ACF Equity Research

AbbVie Inc.: Acquisition of Landos Biopharma to Enhance Autoimmune Disease Treatments & Other Major Developments

Leading pharmaceutical company AbbVie Inc. has outperformed expectations in its first quarter 2024 results. The financial results and current...

Baptista Research

AbbVie Inc: Produodopa's Green Light In Scotland & 6 Other Major Developments - Key Drivers

AbbVie Inc. showcased a robust performance in the fourth quarter (Q4) of 2023, delivering results surpassing initial expectations. The company's...

Baptista Research

AbbVie Inc.: Is The Strengthening Neuroscience Pipeline The Key To Future Success? - Major Drivers

AbbVie Inc. managed to exceed Wall Street's revenue and earnings expectations, reinforcing a positive trajectory for long-term growth. The...

Baptista Research

AbbVie Inc.: Interesting Advancements In Several Preclinical & Early-stage Clinical Assets – Key Drivers

AbbVie managed to surpass the revenue expectations as well as the earnings expectations of Wall Street. Skyrizi and Rinvoq are exhibiting...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)